Three Weeks Left! – Make Plans Now to Attend our 2023 Annual Meeting in White River Junction, Vermont – April 24th to 25th

If you haven’t done so already, make plans now to attend our 2023 Annual Meeting, to be held Monday, April 24th through Tuesday, April 25th, 9 am to 4 pm in the Vermont Room of the historic Hotel Coolidge.

This is your best opportunity to learn more about quinism from experts in the field and meet with others affected by the condition. You can register now at no charge by emailing us to reserve your space. This year, we are pleased to offer free registration to all our guests on a first-come, first-served basis, so register early to ensure availability.

To learn more about traveling to White River Junction and arranging accommodations, please read out recent newsletter announcing the meeting.

U.S. Military Members Claim Genentech Failed to Warn of Neuropsychiatric Risks of Antimalarial Drug Mefloquine

As recently reported, the law firms Kozyak Tropin & Throckmorton and Moore & Lee have filed a class action lawsuit in the Northern District of California against Genentech and its corporate parent, Roche Group. The lawsuit is based on the manufacturer’s failure to warn the U.S. military and its service members of the neuropsychiatric risks of mefloquine. The current complaint is available to read online in its entirety.

Further information on the class action lawsuit is available on the website of Kozyak Tropin & Throckmorton.

Zookeepers Inadvertently Kill Penguins with Mefloquine

As recently reported in the Journal of Avian Medicine and Surgery, each penguin received 125 mg of mefloquine per week (half the typical human prophylactic dose) during the summer avian malaria season. The first penguin died after five doses, and seven more penguins died in subsequent weeks to months, their deaths typically foreshadowed by regurgitation within the hour of the fish used to administer the drug.
At autopsy, all of the dead penguins had signs of pulmonary congestion, from which death was suspected in each case, although the zookeepers conceded that other effects were possible and that in particular “lesions could have been present in the brain of the penguins but were difficult to assess during routine histopathology”.

Based on their experiences, the zookeepers concluded, “we do not recommend treating penguins with mefloquine until further research and safety trials can be done”.